ArticleEcancermedicalscience2025
An overview of the presentation and management of vulvovaginal cancers at the NSIA-LUTH Cancer Centre.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Digital oncology frameworks in Africa: a scoping review of architectural patterns, digital maturity, and data equity implications.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vulvovaginal cancer (VVC) are two rare malignancies in women which are less prevalent than other gynecological cancer. Aim: This study seeks to investigate the evaluation of the presentation and management of VVC cases at our institution, aiming to contribute to a deeper understanding of VVC within sub-Saharan Africa. Methods: This was a retrospective study of all VVC cases seen at the NSIA-LUTH Cancer Centre from May 2019 to June 2024. Data on clinical presentation and treatment modalities were collated and analysed using the Statistical Package for Social Science version 27.0. Results: Out of a total of 10,376 cancer cases reported during the study period, 0.6% (67 cases) were accounted as VVC, the median age at presentation was 54 years range: 32-88 years). Vaginal bleeding (41.8%), lump (41.8%) and vaginal swelling (32.8%) were the major presenting symptoms. Immunosuppression Human Immunodeficiency Virus, alcohol, multiple sexual partners and family history of cancer were the most identified risk factors. Histological examination identified squamous cell carcinoma as the predominant subtype (74.8%). Most cases were diagnosed at stage IV (52.2%). Treatment uptake was average, with 23.9% received surgery, 40.3% receiving chemotherapy and 56.7% undergoing radiotherapy. Conclusion: The incidence of VVC is increasing in Nigeria, particularly among young women. This study showed late presentation and advanced-stage cancer with vaginal bleeding, lump and vaginal swelling as the most presenting symptoms. It is imperative to increase awareness, which potentially facilitates early detection of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.